D

rug makers in the United Kingdom have gone to court in hopes of preventing the country’s National Health Service from imposing pricing limits on medicines.

The Association of British Pharmaceutical Industry is responding to a move by the government to limit funding for any prescription drug that will cost the NHS more than roughly $25 million in any of the first three years of use.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that the industry seems to hold the position that just because you can’t afford to pay for something is no excuse for not buying it. Another example of where ‘kitchen table finances’ don’t apply – or some don’t want them to apply – to national issues. To quote our scribe ‘concerns persist that some drugs may not be covered in the future due to strained finances.’
    If there are such problems, then lower the price$ … oh, wait, I’m spouting heresy again. My apologies!

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.